SCHEMBL622115

SCHEMBL622115

COc1ccc2nccnc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
KMT2A Q03164 3/20 0.56
MAPT P10636 3/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 2/20 0.56
POLB P06746 2/20 0.56
ALDH1A1 P00352 2/20 0.56
TP53 P04637 2/20 0.56
TSHR P16473 1/20 0.56
STAT1 P42224 1/20 0.56
LMNA P02545 2/20 0.55
NQO2 P16083 1/20 0.55
NOS3 P29474 1/20 0.52
NOS1 P29475 1/20 0.52
NOS2 P35228 1/20 0.52
HTR1A P08908 3/20 0.50
ADRA1D P25100 3/20 0.50
ADRA1A P35348 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29550130 1.00 KDM4E (0.56) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL15668045 0.87 NPC1 (0.50) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL28950139 0.84 DYRK1A (0.61) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL621960 0.78 KMT2A (0.58) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL621166 0.78 SLC22A12 (0.47) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL12817638 0.77 MAPT (0.41) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL27720616 0.77 MAPT (0.44) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL622749 0.77 FGFR1 (0.47) KDM4EKMT2AMAPTNPC1RAB9A
SCHEMBL27663665 0.77 HTR1A (0.58) KDM4ELMNANOS3NOS1NOS2
SCHEMBL10214298 0.76 MEN1 (0.87) KDM4EKMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP claimed
CN-121931199-A Method for synthesizing quinoxaline and derivative thereof by using chemical enzyme synergistic catalytic system 南京工业大学 2026-04-28 CN disclosed
US-20250221998-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-07-10 US disclosed
EP-4504730-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 Dana-Farber Cancer Institute, Inc. (US) 2025-02-12 EP disclosed
CN-119365454-A Discovery of covalent EGFR inhibitors through cysteine 775 丹娜-法伯癌症研究院 2025-01-24 CN disclosed
CN-114516880-B Method for synthesizing furo [2,3-b ] quinoxaline derivative 桂林理工大学 2023-11-17 CN disclosed
CN-116891425-A Alpha-trifluoromethyl diazonium sulfonium salt compound and application thereof 遵义医科大学 2023-10-17 CN disclosed
WO-2023196409-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-12 WO disclosed
WO-2023196409-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-12 WO disclosed
CN-112142797-B Phosphorus-containing quinoxaline compound, and preparation method and application thereof 江西师范大学 2023-07-14 CN disclosed
CN-1106005-A A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
CN-1106004-A A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
EP-0657467-A1 Antitumor antibiotics Bristol-Myers Squibb Company (US) 1995-06-14 EP disclosed
EP-0642516-A1 MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1995-03-15 EP disclosed
EP-0638082-A1 MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1995-02-15 EP disclosed
EP-0642516-A4 MACROCYCLIC IMMUNOMODULATORS. ABBOTT LAB (US) 1994-06-15 EP disclosed
EP-0638082-A4 MACROCYCLIC IMMUNOMODULATORS. ABBOTT LAB (US) 1994-06-09 EP disclosed
WO-1993004680-A1 MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1993-03-18 WO disclosed
WO-1993004679-A1 MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1993-03-18 WO disclosed
CN-1042912-A (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1990-06-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221998-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 EGFR, ERBB2, ERBB3 KDM4E 2321/4885KMT2A 4002/4885MAPT 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.